LifeVest Arrhythmia Notification Study
A 26-Week, Phase 3, Open Label Study with a 12-Week, PlaceboControlled, Randomized Withdrawal Period Followed by an Open Label Long Term Safety Extension to Evaluate the Safety and Efficacy of Tenapanor to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis and Peritoneal Dialysis
Observational Registry of Treatment Patterns in U.S. Heart Failure Patients with Reduced Ejection Fraction
ChaRactErization of patients following aCute venous thrOmboembolism (VTE) and assessment of safety and effectiveness of dabigatran etexilate (DE) in the tReatment and secondary prevention of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) in comparison to vitamin K antagonist (VKA) in routine clinical practice.
A multicenter, randomized, double-blind, double-dummy, parallel group, active-controlled, forced-titration, 12-week comparison of combined angiotensin-neprilysin inhibition with sacubitril and valsartan versus enalapril on changes in central aortic stiffness in patients with heart failure and reduced ejection fraction.